What is the Anthem Biosciences PE ratio today?
Anthem Biosciences' PE ratio is 81.2 at the 29 October 2026 close (₹830.15 a share): a market capitalisation of ₹46,769 crore divided by consolidated net profit of ₹576 crore over the last four quarters (Q2 FY26 to Q1 FY27).
What is the Anthem Biosciences net worth?
Anthem Biosciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹3,043 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹46,769 crore at the 29 October 2026 close.
What is the Anthem Biosciences book value per share?
Anthem Biosciences' book value per share was ₹54.00 on 31 March 2026: shareholders' equity of ₹3,043 crore divided by the 56.34 crore shares in issue. The share price at the 29 October 2026 close was ₹830.15.
What is the Anthem Biosciences PB ratio (price to book value)?
Anthem Biosciences' price-to-book (PB) ratio is 15.37 at the 29 October 2026 close: a market capitalisation of ₹46,769 crore divided by shareholders' equity (book value) of ₹3,043 crore on 31 March 2026. That is a book value of ₹54.00 per share against a share price of ₹830.15.
What is the Anthem Biosciences promoter holding?
Promoters held 71.40% of Anthem Biosciences on 30 September 2026, down 0.02 percentage points from 71.42% the previous quarter and down 3.29 percentage points from 74.69% a year earlier, according to the shareholding pattern filed with NSE.
What is the Anthem Biosciences shareholding pattern?
On 30 September 2026, Anthem Biosciences' shares were held by promoters 71.40%, foreign portfolio investors (FII/FPI) 3.79%, domestic institutions (DII) 12.10% (including mutual funds at 9.25%) and retail and other non-institutional investors 12.70%. Over the year, FII holding was up 2.12 percentage points from 1.67% and DII holding was up 4.88 percentage points from 7.22%.
What is the Anthem Biosciences market cap?
Anthem Biosciences' market capitalisation was ₹46,769 crore at the 29 October 2026 close: 56.34 crore shares at ₹830.15 each.
Is Anthem Biosciences debt free?
No. Anthem Biosciences had borrowings of ₹51.1 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.02. Its cash and current investments were ₹940 crore, so it held net cash of ₹889 crore.
What is the Anthem Biosciences debt to equity ratio?
Anthem Biosciences' debt-to-equity ratio was 0.02 on 31 March 2026: borrowings of ₹51.1 crore against total equity of ₹3,043 crore.
What is the Anthem Biosciences dividend yield?
Anthem Biosciences' dividend yield is 0.24% at the 29 October 2026 close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹830.15. They were ₹2 on 25 June 2026.
What is the Anthem Biosciences dividend in 2026 and its record date?
In 2026, Anthem Biosciences has declared one dividend: ₹2 with record date 26 June 2026 and ex-date 25 June 2026.
What are the Anthem Biosciences latest quarterly results?
Anthem Biosciences' latest results are for Q1 FY27 (April–June 2026), filed on 21 July 2026: consolidated net profit ₹120 crore, down 11.7% from ₹136 crore in Q1 FY26; revenue from operations ₹418 crore, down 22.6% year on year.
When are the Anthem Biosciences next results?
Anthem Biosciences will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.
How does Anthem Biosciences compare with its peers?
On FY26 consolidated figures, against Syngene International, Divi's Labs and Glaxosmithkline Pharmaceuticals: Anthem Biosciences' operating margin of 32.9% is the highest of the four (Syngene International 12.5%, Divi's Labs 28.2%, Glaxosmithkline Pharmaceuticals 32.5%; peer average 24.4%).
How does the Anthem Biosciences PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Anthem Biosciences' PE ratio is 79.0, the second highest of the four: Syngene International 50.8, Divi's Labs 99.7 and Glaxosmithkline Pharmaceuticals 41.1, a peer average of 63.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Anthem Biosciences vs Syngene International: how do they compare?
In FY26, Anthem Biosciences earned net profit of ₹592 crore on revenue of ₹2,124 crore, against ₹317 crore on ₹3,739 crore for Syngene International. Anthem Biosciences' operating margin was 32.9% (Syngene International 12.5%). At the 29 October 2026 close, Anthem Biosciences' market capitalisation was ₹46,769 crore against ₹16,091 crore for Syngene International, and its PE ratio on FY26 profit 79.0 against 50.8.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
